
    
      Patients are enrolled following completion from the early clinical study of CD19-7X19 CAR-T
      treatment ( NCT03258047) and will be followed for 5 years post treatment from the last
      treatment. They will be monitored for safety and efficacy with the primary treatment
      protocols for the protocol defined duration. This long-term following up study allow an
      interim analysis to evaluate the outcomes of the study when it arrives in 2 years Collection
      of such long term effects of CAR-T cell therapy will help to further define the risk-benefit
      profile of CAR-T Therapies.
    
  